Vicki Vakiener
Ms. Vakiener joined the board of directors for Chimerix in April 2021. Over the course of her career, she has served as Epizyme’s Chief Commercial Officer where she led the company’s commercial efforts and oversaw the successful launch of Tazemetostat in two indications. For over 20 years, Vicki has held positions of leadership across Johnson & Johnson’s pharmaceuticals and diagnostics businesses focused in oncology . In addition, Vicki was the Vice President and Oncology Global Commercial Leader for Prostate Cancer at Janssen and led a cross-functional team to develop and execute the global commercial strategy for its portfolio of late stage and early pipeline compounds. She also previously served as the Vice President of Oncology Marketing at Janssen Oncology U.S., where she directed all marketing activities for ZYTIGA®, IMBRUVICA®, DARZALEX® and YONDELIS® and drove launch planning for ERLEADA® and ZEJULA®.
Vicki received a B.S. in Biochemistry from Albright College.